SESN - イレブン・バイオセラピュ―ティクス (Sesen Bio Inc.) イレブン・バイオセラピュ―ティクス

 SESNのチャート


 SESNの企業情報

symbol SESN
会社名 Sesen Bio Inc (イレブン・バイオセラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sesen Bio Inc. formerly Eleven Biotherapeutics Inc. is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium Vicinium in combination with checkpoint inhibator durvalumab and VB6-845d. The Company’s lead program Vicinium is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin Pseudomonas Exotoxin A (ETA) directly to cancer cells.   イレブン・バイオセラピュ―ティクスは、米国のバイオ医薬品企業。AMP-Rxと呼ばれる独自のタンパク質工学プラットフォ―ムを使用し、目の疾患の治療用にタンパク質治療薬の開発を行う。ドライアイ疾患およびアレルギ―性結膜炎の局所治療としての製品候補の開発を手掛ける。前臨床製品候補には、糖尿病性黄斑浮腫やブドウ膜炎の治療薬がある。   Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
本社所在地 245 First Street Suite 1800 Cambridge MA 02142 USA
代表者氏名 Daniel S. Lynch ダニエルS.リンチ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-444-8550
設立年月日 39479
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 17人
url www.elevenbio.com
nasdaq_url https://www.nasdaq.com/symbol/sesn
adr_tso
EBITDA EBITDA(百万ドル) -28.56800
終値(lastsale) 1.84
時価総額(marketcap) 141700238.16
時価総額 時価総額(百万ドル) 124.75780
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 61.79680
当期純利益 当期純利益(百万ドル) -28.57300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sesen Bio Inc revenues decreased from $425K to $0K. Net loss decreased 3% to $12.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Loss from change in fair value of contin decrease of 27% to $2.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.27.

 SESNのテクニカル分析


 SESNのニュース

   Sesen Bio Inc. (SESN) Has Recovered 21.35% From Its Low: Is This The Beginning Of A Trend?  2021/12/10 20:00:00 Stocks Register
Sesen Bio Inc. (NASDAQ:SESN) price on Friday, December 10, fall -0.16% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.89. A look at the stocks price movement, the level at last check in todays session was $0.89, moving within a range at $0.8399 and $0.9499. The beta Sesen Bio Inc. (SESN) Has Recovered 21.35% From Its Low: Is This The Beginning Of A Trend? Read More »
   Keep an Eyeball on P/S Ratio: Sesen Bio, Inc. (NASDAQ:SESN -17.58%), TAL Education Group (NYSE:TAL -4.69%)  2021/12/09 23:32:37 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Keep an Eyeball on P/S Ratio: Sesen Bio, Inc. (NASDAQ:SESN -17.58%), TAL Education Group (NYSE:TAL -4.69%) appeared first on Stocks Equity .
   Sesen Bio reports anticipated regulatory path forward for Vicineum, shares down 18%  2021/12/09 13:42:53 Seeking Alpha
   Contrasting Sesen Bio (NASDAQ:SESN) & Lipocine (NASDAQ:LPCN)  2021/12/07 11:24:45 Transcript Daily
Sesen Bio (NASDAQ:SESN) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk. Profitability This table compares Sesen Bio and Lipocines net margins, return on equity and return on []
   Head to Head Survey: Sesen Bio (NASDAQ:SESN) and Lipocine (NASDAQ:LPCN)  2021/12/01 00:16:41 Dakota Financial News
Sesen Bio (NASDAQ:SESN) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Profitability This table compares Sesen Bio and Lipocines net margins, return on equity and return on []
   Cramer Shares His Thoughts On Sesen Bio, Marathon Oil, More  2021/06/22 12:20:36 Benzinga
On CNBC''s "Mad Money Lightning Round," Jim Cramer advised a viewer with a long position in Sesen Bio Inc (NASDAQ: SESN ) to take some off the table. Cramer wants to stick with Louisiana-Pacific Corporation (NYSE: LPX ). People should have Full story available on Benzinga.com
   Active Stock Evaluation: Sesen Bio, Inc. (NASDAQ:SESN), China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC)  2021/06/20 21:26:12 Stock Equity
Sesen Bio, Inc. (SESN) with the stream of -3.33% also noticed, India China SXT Pharmaceuticals, Inc. (SXTC) encountered a rapid change of 0.00% in the last hour of trading session. The post Active Stock Evaluation: Sesen Bio, Inc. (NASDAQ:SESN), China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) appeared first on Stocks Equity .
   Have an eye on: Sesen Bio, Inc. (NASDAQ:SESN), Square, Inc. (NYSE:SQ)  2021/06/08 22:01:11 Stock Equity
Sesen Bio, Inc. (SESN) with the stream of 1.14% also noticed, India Square, Inc. (SQ) encountered a rapid change of -1.56% in the last hour of Tuesdays trading session. Sesen The post Have an eye on: Sesen Bio, Inc. (NASDAQ:SESN), Square, Inc. (NYSE:SQ) appeared first on Stocks Equity .
   Understanding Sesen Bio''s Unusual Options Activity  2021/06/02 15:20:51 Benzinga
Shares of Sesen Bio (NASDAQ: SESN ) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved down to $3.65. Sentiment: BEARISH Option Type: SWEEP Trade Type: CALL Expiration Date: 2021-08-20 Strike Price: $4.00 Volume: 722 Open Interest: 3537 Three Indications Of Unusual Options Activity Extraordinarily large volume (compared to historical averages) is one indication of unusual options market activity. Volume refers to the total number of contracts traded over a given time period when discussing options market activity. The number of contracts that have been traded, but not yet closed by either counterparty, is called open interest. A contract cannot be considered closed until there exists both a buyer and seller for it. The trading of a contract with an expiration date in the distant future is another sign of unusual Full story available on Benzinga.com
   Sesen Bio inks global supply partnership with Qilu Pharmaceutical  2021/06/02 14:54:04 Seeking Alpha
   Sesen Bio Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2021/03/15 18:31:00 Stock Market Daily
Sesen Bio announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company’s Lead Product Candidate Vicineum™  2021/03/02 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr. Neal Shore, medical director of the Carolina Urologic Research Center who will provide a clinical perspective on Vicineum, Sesen Bio’s product candidate for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). I
   Why Hepion Pharma, Sesen Bio And More Are Moving Today  2021/02/16 16:44:42 Benzinga
Hepion Pharmaceuticals (NASDAQ: HEPA ) shares are … Full story available on Benzinga.com
   Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike - Stocks News Feed  2021/02/16 14:13:45 Stocks News Feed
Under priority review status, the FDA has accepted Sesen Bio Inc’s (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Additionally, the FDA stated that it is not currently planning to hold an advisory committee meeting to discuss the application. The agency’s target action date is August… Read More »Sesen Bio’s Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike
   Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™  2021/02/16 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced today that the U.S. Food and Drug Administration (FDA) accepted for filing the Company’s Biologics License Application (BLA) for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and granted the application Priority Review. In addition, the FDA stated tha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イレブン・バイオセラピュ―ティクス SESN Sesen Bio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)